{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:33:34Z","timestamp":1738042414339,"version":"3.33.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"crossref","award":["20210302124597"],"award-info":[{"award-number":["20210302124597"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013061","name":"Jilin Scientific and Technological Development Program","doi-asserted-by":"crossref","award":["20200201315JC"],"award-info":[{"award-number":["20200201315JC"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jilin Tianhua Health Charity Foundation","award":["J2023JKJ017","J2023JKJ021"],"award-info":[{"award-number":["J2023JKJ017","J2023JKJ021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01490-8","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:52:40Z","timestamp":1737985960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer"],"prefix":"10.1007","author":[{"given":"Saisai","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaida","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"3","key":"1490_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1490_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"1490_CR3","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/onc.2014.115","volume":"34","author":"R Ferraldeschi","year":"2015","unstructured":"Ferraldeschi R et al (2015) Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 34(14):1745\u20131757","journal-title":"Oncogene"},{"issue":"10","key":"1490_CR4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C et al (2015) Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41(10):884\u2013892","journal-title":"Cancer Treat Rev"},{"key":"1490_CR5","doi-asserted-by":"crossref","unstructured":"Schmidt M et al (2017) Regulation of G2\/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. Molecules, 22(12)","DOI":"10.3390\/molecules22122045"},{"issue":"10","key":"1490_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","volume":"37","author":"CJ Matheson","year":"2016","unstructured":"Matheson CJ, Backos DS, Reigan P (2016) Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci 37(10):872\u2013881","journal-title":"Trends Pharmacol Sci"},{"issue":"31","key":"1490_CR7","doi-asserted-by":"publisher","first-page":"49902","DOI":"10.18632\/oncotarget.10231","volume":"7","author":"HY Kim","year":"2016","unstructured":"Kim HY et al (2016) Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget 7(31):49902\u201349916","journal-title":"Oncotarget"},{"issue":"33","key":"1490_CR8","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.21.01435","volume":"39","author":"JF Seligmann","year":"2021","unstructured":"Seligmann JF et al (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. J Clin Oncol 39(33):3705\u20133715","journal-title":"J Clin Oncol"},{"issue":"4","key":"1490_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11523-023-00965-7","volume":"18","author":"TM Bauer","year":"2023","unstructured":"Bauer TM et al (2023) A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol 18(4):517\u2013530","journal-title":"Target Oncol"},{"issue":"6","key":"1490_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41408-021-00502-7","volume":"11","author":"X Qiao","year":"2021","unstructured":"Qiao X et al (2021) The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer J 11(6):111","journal-title":"Blood Cancer J"},{"issue":"5","key":"1490_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41401-018-0108-5","volume":"40","author":"XH Fu","year":"2019","unstructured":"Fu XH et al (2019) CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression. Acta Pharmacol Sin 40(5):677\u2013688","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"1490_CR12","first-page":"1262","volume":"106","author":"X Li","year":"2021","unstructured":"Li X et al (2021) The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica 106(5):1262\u20131277","journal-title":"Haematologica"},{"issue":"13","key":"1490_CR13","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1111\/jcmm.15281","volume":"24","author":"C Hu","year":"2020","unstructured":"Hu C et al (2020) CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. J Cell Mol Med 24(13):7239\u20137253","journal-title":"J Cell Mol Med"},{"issue":"14","key":"1490_CR14","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1158\/0008-5472.CAN-17-3691","volume":"78","author":"S Pal","year":"2018","unstructured":"Pal S et al (2018) Dual HDAC and PI3K Inhibition Abrogates NFkappaB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res 78(14):4007\u20134021","journal-title":"Cancer Res"},{"issue":"11","key":"1490_CR15","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","volume":"8","author":"H Hirai","year":"2009","unstructured":"Hirai H et al (2009) Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 8(11):2992\u20133000","journal-title":"Mol Cancer Ther"},{"issue":"36","key":"1490_CR16","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S et al (2016) Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol 34(36):4371\u20134380","journal-title":"J Clin Oncol"},{"issue":"3","key":"1490_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","volume":"3","author":"CS Sorensen","year":"2003","unstructured":"Sorensen CS et al (2003) Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3(3):247\u2013258","journal-title":"Cancer Cell"},{"issue":"3","key":"1490_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nprot.2006.179","volume":"1","author":"V Vichai","year":"2006","unstructured":"Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112\u20131116","journal-title":"Nat Protoc"},{"issue":"5","key":"1490_CR19","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1111\/jcmm.14267","volume":"23","author":"H Xia","year":"2019","unstructured":"Xia H et al (2019) Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer. J Cell Mol Med 23(5):3656\u20133664","journal-title":"J Cell Mol Med"},{"key":"1490_CR20","doi-asserted-by":"crossref","unstructured":"Zhang D et al (2019) Polyphyllin I induces cell cycle arrest in prostate cancer cells via the upregulation of IL6 and P21 expression. Medicine, 98(44)","DOI":"10.1097\/MD.0000000000017743"},{"key":"1490_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.biocel.2014.06.013","volume":"54","author":"WC Krause","year":"2014","unstructured":"Krause WC, Shafi AA, Nakka M, Weigel NL (2014) Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol 54:49\u201359. https:\/\/doi.org\/10.1016\/j.biocel.2014.06.013Epub 2014 Jul 4. PMID: 25008967; PMCID: PMC4160387","journal-title":"Int J Biochem Cell Biol"},{"key":"1490_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2020.12.037","volume":"504","author":"T Ma","year":"2021","unstructured":"Ma T, Bai S, Qi Y et al (2021) Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy. Cancer Lett 504:37\u201348. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.037","journal-title":"Cancer Lett"},{"key":"1490_CR23","unstructured":"Yang C, Liu Y, Lu Y Evaluating\u2009<\u2009em\u2009>\u2009In Vitro\u2009DNA Damage Using Comet Assay. Journal of Visualized Experiments, 2017(128)"},{"key":"1490_CR24","doi-asserted-by":"crossref","unstructured":"Guo E et al (2022) WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. J Exp Med, 219(1)","DOI":"10.1084\/jem.20210789"},{"issue":"6","key":"1490_CR25","first-page":"1598","volume":"52","author":"ME Gleave","year":"1992","unstructured":"Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW (1992) Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52(6):1598\u20131605","journal-title":"Cancer Res"},{"issue":"18","key":"1490_CR26","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1016\/S0021-9258(17)39978-7","volume":"252","author":"TC Chou","year":"1977","unstructured":"Chou TC, Talaly P (1977) A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252(18):6438\u20136442","journal-title":"J Biol Chem"},{"issue":"10271","key":"1490_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S et al (2021) Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397(10271):281\u2013292","journal-title":"Lancet"},{"issue":"2","key":"1490_CR28","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ijrobp.2016.01.028","volume":"95","author":"KC Cuneo","year":"2016","unstructured":"Cuneo KC et al (2016) Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. Int J Radiat Oncol Biol Phys 95(2):782\u2013790","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1490_CR29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/13543784.2018.1511700","volume":"27","author":"S Fu","year":"2018","unstructured":"Fu S et al (2018) Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs 27(9):741\u2013751","journal-title":"Expert Opin Investig Drugs"},{"key":"1490_CR30","doi-asserted-by":"publisher","first-page":"1271847","DOI":"10.3389\/fonc.2023.1271847","volume":"13","author":"A Bruyer","year":"2023","unstructured":"Bruyer A et al (2023) Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma. Front Oncol 13:1271847","journal-title":"Front Oncol"},{"key":"1490_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.leukres.2017.11.004","volume":"64","author":"TB Garcia","year":"2018","unstructured":"Garcia TB, Fosmire SP, Porter CC (2018) Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res 64:30\u201333","journal-title":"Leuk Res"},{"issue":"1","key":"1490_CR32","doi-asserted-by":"publisher","first-page":"9930","DOI":"10.1038\/s41598-020-66018-5","volume":"10","author":"DH Ha","year":"2020","unstructured":"Ha DH et al (2020) Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Sci Rep 10(1):9930","journal-title":"Sci Rep"},{"issue":"11","key":"1490_CR33","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1158\/1078-0432.CCR-10-3082","volume":"17","author":"LA Parsels","year":"2011","unstructured":"Parsels LA et al (2011) Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 17(11):3706\u20133715","journal-title":"Clin Cancer Res"},{"issue":"30","key":"1490_CR34","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1200\/JCO.2014.60.4009","volume":"33","author":"K Do","year":"2015","unstructured":"Do K et al (2015) Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol 33(30):3409\u20133415","journal-title":"J Clin Oncol"},{"issue":"2","key":"1490_CR35","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ygyno.2022.08.006","volume":"167","author":"A Madariaga","year":"2022","unstructured":"Madariaga A et al (2022) Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma. Gynecol Oncol 167(2):226\u2013233","journal-title":"Gynecol Oncol"},{"issue":"12","key":"1490_CR36","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-14-0173","volume":"12","author":"OS Chao","year":"2014","unstructured":"Chao OS, Goodman OB Jr. (2014) Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP. Mol Cancer Res 12(12):1755\u20131766","journal-title":"Mol Cancer Res"},{"issue":"6","key":"1490_CR37","doi-asserted-by":"publisher","first-page":"e11208","DOI":"10.1371\/journal.pone.0011208","volume":"5","author":"SK Kachhap","year":"2010","unstructured":"Kachhap SK et al (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 5(6):e11208","journal-title":"PLoS ONE"},{"issue":"20","key":"1490_CR38","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1128\/MCB.00412-12","volume":"32","author":"H Beck","year":"2012","unstructured":"Beck H et al (2012) Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 32(20):4226\u20134236","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1490_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","volume":"28","author":"KN Moore","year":"2022","unstructured":"Moore KN et al (2022) Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clin Cancer Res 28(1):36\u201344","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:52:48Z","timestamp":1737985968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":39,"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01490-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}